-
Product Insights
NewGeneralized Seizures – Drugs In Development, 2024
Empower your strategies with our Generalized Seizures – Drugs In Development, 2024 report and make more profitable business decisions. Generalized seizures, are a type of seizure that impairs consciousness and distorts the electrical activity of the whole or a larger portion of the brain. It occurs when the abnormal electrical activity causing a seizure begins in both halves (hemispheres) of the brain at the same time. Generalized seizures occur in various seizure syndromes, including myoclonic epilepsy, familial neonatal convulsions, childhood absence...
-
Product Insights
NewTonic-Clonic (Grand Mal) Seizure – Drugs In Development, 2024
Empower your strategies with our Tonic-Clonic (Grand Mal) Seizure – Drugs In Development, 2024 report and make more profitable business decisions. A tonic-clonic seizure, previously known as a grand mal seizure, is defined as a seizure that has a tonic phase followed by clonic muscle contractions that causes a loss of consciousness and violent muscle contractions. The Tonic-Clonic (Grand Mal) Seizure drugs in development market research report provide comprehensive information on the therapeutics under development for Tonic-Clonic (Grand Mal) Seizure, complete...
-
Product Insights
NewPartial Seizure – Drugs In Development, 2024
Empower your strategies with our Partial Seizure – Drugs In Development, 2024 report and make more profitable business decisions. Focal onset seizures, or partial seizures, are prevalent neurological disorders marked by abnormal electrical activity in specific brain regions. Manifesting in diverse forms, symptoms range from subtle sensory disruptions to noticeable motor movements and altered consciousness. Precise diagnosis relies on clinical evaluation, neuroimaging, and electroencephalography. Managing focal onset seizures involves a range of strategies, including antiepileptic medications, surgical interventions, and lifestyle adjustments....
-
Product Insights
NewDravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2024
Empower your strategies with our Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2024 report and make more profitable business decisions. Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare genetic disorder that causes a severe form of epilepsy. It usually starts in the first year of life with prolonged seizures triggered by fever or high temperature. Children with Dravet syndrome have various types of seizures that are difficult to treat with medications. They...
-
Product Insights
NewSeizures – Drugs In Development, 2024
Empower your strategies with our Seizures – Drugs In Development, 2024 report and make more profitable business decisions. A seizure is a medical condition where the patient has a temporary, unstoppable surge of electrical brain activity. Affected brain cells uncontrollably fire signals to others around them, overloading the affected areas of the brain. That overload can cause a wide range of symptoms or effects, including abnormal sensations, passing out, and uncontrolled muscle movements. Up to 11% of people in the US...
-
Product Insights
NewChildhood Epilepsy – Drugs In Development, 2024
Empower your strategies with our Childhood Epilepsy – Drugs In Development, 2024 report and make more profitable business decisions. Childhood epilepsy is a neurological disorder characterized by recurring seizures in children. Seizures result from abnormal electrical activity in the brain, causing temporary disruptions in behavior, awareness, sensation, or consciousness. This condition can manifest in various forms, from brief staring spells to convulsions or loss of consciousness. The causes of childhood epilepsy can vary, including genetic factors, brain injury, infections, developmental disorders,...
-
Product Insights
NewMajor Depressive Disorder – Drugs In Development, 2024
Empower your strategies with our Major Depressive Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1012 in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1012 in Influenzavirus B Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1012 in Influenzavirus B InfectionsDrug Details: mRNA-1012 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XEN-1101 in Tonic-Clonic (Grand Mal) Seizure
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XEN-1101 in Tonic-Clonic (Grand Mal) Seizure Drug Details: XEN-1101 (1OP-2198) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vaxinia in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vaxinia in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VAXINIA in Melanoma Drug Details:VAXINIA (CF33+hNIS) is under development for the treatment of solid...